The stock price of Eli Lilly is likely to be negatively impacted in the short term due to the company's announcement of slower-than-expected sales of its GLP-1 drug, Mounjaro, and the subsequent cut in full-year revenue guidance. This indicates potential challenges in meeting market expectations, which can lead to a decrease in investor confidence.